Immunocytochemical Characterization of Alzheimer Disease Hallmarks in APP/PS1 Transgenic Mice Treated with a New Anti-Amyloid-β Vaccine

Figure 1

Diagram of the experimental protocol. EB101 vaccine was injected subcutaneously (s.c.) into mice of group A from 7 weeks of age (preventive treatment/phase I) or 35 weeks of age (therapeutic treatment/phase II), respectively, for 7 months. Mice of groups B and C were also injected s.c. with EB102 or PBS following the previous protocol.